Skip to content
Back to Blog
Bio
2026-04-248 min read19

K-Bio Vaccine Fund 5 & 6: Investment Attraction Strategy for Bio SMEs in 2026

A comprehensive guide to the 2026 K-Bio Vaccine Fund 5 & 6 (KRW 50B each) structure and investment attraction strategies for Korean bio SMEs, covering CMC data standards, IP portfolios, and stage-by-stage roadmaps.

KITIM Consulting Team

K-Bio Vaccine Fund: Status and Significance

The K-Bio Vaccine Fund, led by Korea's Ministry of Health and Welfare, is a dedicated policy fund for the bio-health industry. It has achieved a cumulative commitment of KRW 386.6 billion and invested KRW 95.8 billion across 20 portfolio companies. Fund 1 (KRW 150B), Fund 2 (KRW 156.6B), and Fund 4 (KRW 80B) have served as critical catalysts for the domestic biotech venture ecosystem.

Portfolio Characteristics by Fund

  • Fund 1: Focus on novel drug development, preference for Phase 2+ companies
  • Fund 2: Balanced allocation across vaccines, diagnostics, and digital health
  • Fund 4: Concentrated in innovative pharmaceutical companies and CDMOs
  • Average ticket size of KRW 4-6 billion, primarily at Series B-C stage
  • Fund 5 & 6 Structure (2026)

    In 2026, the Ministry of Health and Welfare announced the simultaneous formation of Funds 5 and 6, each KRW 50 billion in size for a total of KRW 100 billion. Government contributes KRW 40 billion (KRW 20B per fund) as seed capital, with KRW 30 billion in private matching per fund.

    Mandatory Investment Ratios

  • 60% mandatory investment in bio-health — including drugs, devices, and digital health
  • 10% mandatory vaccine allocation — for vaccine R&D, manufacturing, and CMO operations
  • Remaining 30% is at the fund manager's discretion
  • New fund manager selection is led by Korea Venture Investment Corp through a two-stage review
  • Fund Manager Requirements

  • VCs with proven bio-health investment track records
  • At least 3 specialists (medicine, pharmacy, bioengineering preferred)
  • Previous fund IRR of 8% or higher
  • Preparation for Bio SMEs

    CMC, Preclinical, and Clinical Data Standards

    A standardized data package by development stage is essential for due diligence.

  • Preclinical: GLP toxicology reports, efficacy POC data
  • Phase 1: PK/PD profile, primary safety endpoints
  • Phase 2: Interim efficacy analysis, biomarker response data
  • CMC: Established API process, formulation stability of 6+ months
  • IP Portfolio and Preferential Qualifications

  • Build a dual defense structure with composition-of-matter and use patents
  • File PCT international applications and enter national phases in US, China, and EU
  • Secure Innovative Pharmaceutical Company Certification for tech evaluation bonus points
  • Complement with Excellent Corporate Research Institute and ISO 13485 certifications
  • Stage-by-Stage Investment Roadmap

    Seed to Series A

    Technology validation and pipeline value demonstration are top priorities. Scientific rationale for the target-disease mechanism, differentiation against competing drugs, and preclinical POC for at least one pipeline are critical. Valuations typically range from KRW 10-30 billion.

    Series B to C

  • Global expansion: FDA Pre-IND Meeting, EMA Scientific Advice outcomes
  • CDMO linkage: Partnerships with Samsung Biologics, Celltrion, etc.
  • Licensing-out discussions or MTA executions
  • Valuations entering the KRW 50-150 billion range
  • Core Pitch Deck Components

  • One-liner: Explain disease, target, and differentiation within 15 seconds
  • Unmet Need: Quantify market size and unmet demand
  • Science: Visualize Mechanism of Action
  • Pipeline & Milestones: Key events over the next 18-24 months
  • Financials: Burn rate, runway, use of proceeds
  • Complementary Strategies Beyond the Fund

    A multi-track approach is more effective than relying solely on the K-Bio Fund.

  • TIPS: Up to KRW 500M in R&D plus Scale-up TIPS of KRW 1.5B
  • Korea Fund of Funds Bio Account: Year-round matching via KVIC
  • Regional Bio Funds: Linkages with Osong, Songdo, and Daegu bio clusters
  • MOHW R&D Priority: Government R&D selection recognized as private investment milestone
  • KITIM Consulting Services

    The Korea Institute of Technology Innovation Management (KITIM) supports the entire bio-company investment journey. We provide one-stop services including investment-grade business plan and IR material advisory, Innovative Pharmaceutical Company Certification strategy, government R&D linkage planning, and technology-value-based valuation with commercialization roadmaps. Bio companies preparing for K-Bio Vaccine Fund 5 & 6 investment should [contact KITIM](/contact) for a customized strategy consultation.

    K-Bio FundVaccine FundBio InvestmentMOHWR&D Investment

    Related Posts

    Bio

    Biologics Approval Fees Rise From KRW 8.03M to 20.71M, Data-Submission Drugs About 6x — MFDS Fee Regulation Amendment Pre-Announced Nov 6, 2026 (Comments Due Nov 26 / Dec 16): Filing Timing, Budget Review and Fee-Reduction Checks for Pharma & Bio SMEs

    Under the fee amendment MFDS proposed on November 6, approval fees for new biologics would rise from KRW 8.03 million to KRW 20.71 million, and fees for data-submission drugs would go up about sixfold. This guide shows pharma and bio SMEs how to review their filing timing, budgets, fee-reduction eligibility and public comments.

    2026-11-09
    Management Consulting

    Factories With 20–49 Workers Will Need a Safety or Health Manager — Korea's First Tripartite Agreement on November 5 (About 30,000 Sites in 5 Industries Including Manufacturing, Decree Amendment in 2027, Target Start 2028), the Owner-Led Alternative and Government Payroll Support: A Preparation Guide for Small Manufacturers

    Under Korea's November 5 tripartite agreement, about 30,000 sites with 20–49 workers in manufacturing and four other industries are expected to need a qualified safety or health manager from 2028. This guide covers what is settled and what is still open, the owner-led alternative, a cost comparison, and a preparation checklist.

    2026-11-09
    Government Programs

    SMEs Can Now Enter the KRW 1,500 Trillion 'Mega Project' Supply Chain from the Design Stage — MSS Joins as a Lead Ministry, Large/Mid-Tier–SME Councils and Regional Councils Launch (Nov 6 Plan to Expand Planning-Stage Participation), and How SMEs Targeting Semiconductor, AI Data Center and Physical AI Supply Chains Should Prepare Validation, Certification and Mass-Production Qualification

    MSS has joined Korea's KRW 1,500 trillion mega projects as a lead ministry and plans to bring SMEs in from the planning stage. This guide covers how the central and regional councils will work and how to line up support programs against the validation, certification and mass-production barriers.

    2026-11-09
    Updated daily

    Let AI find government support programs in this field

    Complete a 3-minute company assessment and we will recommend programs that fit your company, each with a match score. It is free.

    Get AI-Matched Programs for Free

    Need Consulting?

    Our technology innovation consultants will propose the optimal solution for your company.